The ADC binds HER2 on target cells, is internalized, and releases an exatecan-derived topoisomerase I inhibitor that causes DNA damage, S-phase arrest, and apoptosis (with possible bystander effect). Expression of Topoisomerase I alone does not direct the drug to kill the cell.